Favipiravi (T-705) By Chemlyte Solutions, China
Pas encore membre de TradeKey.com? Inscrivez-vous pour vous connecter avec 9 millions d'importateurs et exportateurs. Rejoignez-le maintenant c'est gratuit |
User Identifiez-vous Devenir membre GRATUITEMENT !
Live Chat Live Chat
❯
BOOK A CALL
Book Call On Your Favorite Time
Code
🗘

By Signing Up. I agree to TradeKey.com Terms of Use, Privacy Policy, IPR and receive emails related to our services

❯
Contact Us
Favipiravi (T-705)

Favipiravi (T-705)

FOB Price

Obtenir le dernier prix

( Negotiable )

|

Minimum Order

Localité:

-

Prix de commande minimale:

-

Commande minimale:

1 Kilogram

Packaging Detail:

-

Delivery Time:

-

Supplying Ability:

10 Kilogram per Week

Payment Type:

T/T, PayPal

Contacter maintenant
Chemlyte Solutions

Chemlyte Solutions

China

Membre gratuit

Personne à contacter Mr. Bruce

Building B, Jian Qiao Community, 789 Shenhua Road, Xihu District, Hangzhou, Zhejiang

Contacter maintenant

Description

Favipiravir (T**5) shows antiviral activity by inhibiting RNA polymerases associated with influenza virus replication. Preclinical pharmacophilic sinology shows that it is not only resistant to seasonal influenza viruses, but also to various influenza viruses of pig origin and highly pathogenic avian influenza, and no significant cross-resistance to existing drug-resistant cell strains; It is effective against a variety of subtype avian influenza viruses, such as H1N1, H5N1 and H7N9, as well as the transcription of other viruses, such as sand-grain virus, yellow fever virus, West Nile disease, bubonia virus and hand-foot-mouth virus, as well as the replication of Zaire-type Ebola virus RNA (IC*0 **0 mol/L). Therefore, it is a new antiviral drug with accurate efficacy and good safety mechanism, and has good application prospect. 

Send a direct inquiry to this supplier

To:

Mr. Bruce < Chemlyte Solutions >

Je veux savoir:

Get Verified Buyers & Suppliers

Avail Free Consultation

Code
       


By Signing up. I agree to TradeKey.com Terms of Use, Privacy Policy, IPR and receive emails related to our services

no thanks